AB Science Logo

AB Science

Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.

AB | PA

Overview

Corporate Details

ISIN(s):
FR0010557264 (+1 more)
LEI:
969500U43TVR8CCVBJ97
Country:
France
Address:
3 AVENUE GEORGE V, 75008 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AB Science, founded in 2001, is a clinical-stage pharmaceutical company specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs). The company focuses on developing targeted therapies for diseases with high unmet medical needs. Its pipeline is centered on two lead compounds, masitinib and AB8939, which are being investigated for use in oncology (e.g., Acute Myeloid Leukemia), neurodegenerative disorders (e.g., ALS, Alzheimer's, Multiple Sclerosis), and inflammatory diseases. AB Science also commercializes Masivet®, a tyrosine kinase inhibitor for use in veterinary medicine.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 18:32
Report Publication Announcement
AB Science annonce annonce un léger décalage de la publication de son rapport f…
French 165.7 KB
2025-09-30 18:32
Report Publication Announcement
AB Science announces a slight delay in the publication of its 2025 half-year fi…
English 192.5 KB
2025-08-04 07:58
Share Issue/Capital Change
AB Science annonce le succès d’un placement privé d’environ 2,55 millions d’eur…
French 332.3 KB
2025-08-04 07:58
Share Issue/Capital Change
AB Science announces the successful completion of a 2.55 million euros private …
English 323.2 KB
2025-07-24 07:56
Regulatory Filings
AB Science has received approval from several European countries to initiate th…
English 297.9 KB
2025-07-24 07:56
Legal Proceedings Report
AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l’é…
French 273.3 KB
2025-06-23 08:03
Regulatory Filings
AB Science - New peer-reviewed data provide strong evidence supporting masitini…
English 307.5 KB
2025-06-23 08:03
Regulatory Filings
AB Science - De nouvelles données évaluées par des pairs apportent des preuves …
French 290.6 KB
2025-06-12 07:59
Legal Proceedings Report
AB Science annonce la délivrance d’un brevet canadien protégeant la composition…
French 197.9 KB
2025-06-12 07:59
Regulatory Filings
AB Science announces issuance of a Canadian patent protecting the composition o…
English 221.7 KB
2025-06-09 08:00
Regulatory Filings
AB Science annonce l’approbation par l’EMA de la prolongation de la durée de co…
French 164.5 KB
2025-06-09 08:00
Report Publication Announcement
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
English 194.6 KB
2025-05-23 07:52
Share Issue/Capital Change
AB Science announces the settlement delivery of its latest capital increase for…
English 199.0 KB
2025-05-23 07:52
Share Issue/Capital Change
AB Science :
French 229.0 KB
2025-05-20 07:49
Share Issue/Capital Change
AB Science annonce le succès d'un placement privé de 1,8 millions d'euros
French 282.8 KB

Automate Your Workflow. Get a real-time feed of all AB Science filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AB Science

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AB Science via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Crinetics Pharmaceuticals, Inc. Logo
Develops novel therapeutics for rare endocrine diseases and related tumors.
United States of America
CRNX
CRISPR Therapeutics AG Logo
Develops transformative CRISPR gene-based medicines for diseases like sickle cell.
United States of America
CRSP
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France
ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea
060590
Cue Biopharma, Inc. Logo
Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.
United States of America
CUE
Cullinan Therapeutics, Inc. Logo
Developing differentiated immune-modulating therapies for cancer and autoimmune diseases.
United States of America
CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires and commercializes branded medicines for acute care, gastroenterology, and oncology.
United States of America
CPIX
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan
4894
Cuprina Holdings (Cayman) LTD Logo
Biomedical firm specializing in Maggot Debridement Therapy for wound care in Singapore & Hong Kong.
United States of America
CUPR
curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea
365270

Talk to a Data Expert

Have a question? We'll get back to you promptly.